Patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) had fewer major CV events when given the GLP-1* receptor agonist albiglutide compared with placebo, adding to the CV benefit profile of GLP-1 receptor agonists, according to results of the Harmony Outcomes** trial presented at EASD 2018.
Hybrid closed-loop insulin therapy in patients with suboptimally controlled type 1 diabetes (T1D) helps to keep their sugar levels within range, a 12-week multicentre, multinational trial has shown, supporting the utility of closed-loop technology in clinical practice.
The GLP-1* receptor agonist lixisenatide may slow the progression of micro- and macroalbuminuria in patients with type 2 diabetes (T2D) and acute coronary syndrome, based on an exploratory analysis of the ELIXA** trial presented at EASD 2018.
Treatment with twincretin, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1 receptor agonist combined into a single drug (LY3298176), not only reduced blood glucose in patients with type 2 diabetes (T2D) – it came with an added benefit of weight loss, with no increase in hypoglycaemia in a phase IIb trial.
Treatment with the DPP-4* inhibitor linagliptin in addition to the standard of care has no impact on heart failure, cardiovascular (CV), or renal events compared with standard of care alone in patients with type 2 diabetes (T2D) who had a very high risk of CV events and/or kidney disease progression, according to the CARMELINA** postmarketing outcomes study, thus providing reassurance on the CV safety of at least one member of the drug class.
Long-term therapy with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) may improve glycaemic control and reverse disease progression, as well as induce significant weight loss, according to a study presented at EASD 2018.
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).